about
Determinants of Hepatitis C Virus p7 Ion Channel Function and Drug Sensitivity Identified In VitroStructure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenasesFactors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenasesThe benzimidazole based drugs show good activity against T. gondii but poor activity against its proposed enoyl reductase enzyme targetStructure Guided Development of Potent Reversibly Binding Penicillin Binding Protein InhibitorsMolecular mechanism of ligand recognition by membrane transport protein, Mhp1Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsivenessMutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathyIn silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesisStructure-based discovery of antibacterial drugs.Benzothioxalone derivatives as novel inhibitors of UDP-N-acetylglucosamine enolpyruvyl transferases (MurA and MurZ).Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors.Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design.Discovery of novel FabF ligands inspired by platensimycin by integrating structure-based design with diversity-oriented synthetic accessibility.Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoproteaseThe first small-molecule inhibitors of members of the ribonuclease E family.Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesteroneIdentification of Receptor Tyrosine Kinase Inhibitors Using Cell Surface Biotinylation and Affinity Isolation.Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease.Structure-based identification and characterisation of structurally novel human P2X7 receptor antagonistsA chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections.Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.Pharmacophore model of the quercetin binding site of the SIRT6 protein.Cyclic Boronates Inhibit All Classes of β-Lactamases.Structure-based design of anti-infectives.An in silico structure-based approach to anti-infective drug discovery.Applications of structure-based design to antibacterial drug discovery.Computational methods to identify new antibacterial targets.Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century.Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modes.New Opportunities in the Structure-based Design of Anti-Protozoan Agents.(±) cis-Bisamido epoxides: A novel series of potent FXIII-A inhibitors.Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: structure based design, synthesis, SAR and antimicrobial activity.Structure-based ligand design of novel bacterial RNA polymerase inhibitors.RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus.Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.Structural/mechanistic insights into the efficacy of non-classical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.
P50
Q27488995-C7295F28-61E3-48FB-9F63-AED67E1866CCQ27654569-523F2070-7A99-4066-B905-9D90707D6B9FQ27679263-16C112EB-ABB2-421C-BD90-819B86383815Q27681222-D7CA09C5-3130-40C1-8013-4F358C361818Q27684105-4E746F74-16D6-4254-B64C-8C4BAFEA38A7Q27684427-156B88F3-9792-4235-9C6A-7863B427FD5BQ27690112-5E818D5D-BD97-437C-B81D-5C822400117CQ28281228-C1945969-6821-4625-8DF5-4F3B96185FF5Q28544931-11F24990-FB3E-44D1-A7B8-2B1726620F5CQ33605661-BE51C01F-88D1-499A-AAB7-50D890FE8303Q33699586-2531F955-A406-41B1-A857-AA943C92B017Q34219538-2D07F463-1962-469F-9DE4-5C54E0E0B5B7Q34256338-EEA189CA-7D34-4303-A6E9-C7C8A14DACFEQ34571962-C506837D-5F34-4B67-B25F-5E416E439622Q35052785-268F7ABA-DC08-493E-BAA1-9EDA819A6720Q35431032-3E0BF523-D291-4483-AEA8-F26D543709FFQ35548884-8727172B-0302-4D66-9E56-B04DFF182B27Q35745666-72AD9955-2860-446C-B91F-0F4A66CCD1D6Q35749234-169189AE-88BB-4806-A623-3E46292D2697Q35827684-2B8C1AF9-9277-4F04-840D-FEBCEB372202Q36092090-4CF5C5CA-79EF-4589-9698-5C4F38940514Q36277651-479D49C5-C745-4A89-945C-0C35B82C50E5Q37093155-ACD437FD-D281-4AD0-A75D-2A482CB99B3DQ37635732-4B2B9479-35C2-4A54-8D66-5DE5F693253BQ37692863-D6AB8190-7467-4D65-8CF8-5FF5B7186DA6Q37720801-C76209D1-104E-4E31-8ED6-CC2B6E9F9A43Q37822857-3F550968-8249-4965-8282-D2D0A6817241Q38114581-607EF694-C943-4592-8B70-72A9D9070609Q38223031-BCBDFE98-F97E-4801-AC0F-BE49E672C34AQ38224191-657045A9-1586-4DA6-8FDC-A678A1145D8BQ38470183-65AAA8F6-064A-4BDF-972E-30C9D7FB9E0EQ38697950-DDDAC872-ED63-4EFF-B0C5-0305ECEFE75EQ38830757-F1FEC438-05BD-4E9C-8590-4F643815E727Q39003125-CEBF2834-6204-433C-9BA8-A24734B87FFFQ39142894-A10CA4ED-DD72-4DF1-9369-FB70B64DF100Q39507682-D286921F-8F22-4E2D-8124-B3DEFD1B0981Q39537295-1C1B6B19-7148-4D8C-9F20-3948379BA815Q39552847-99E89D92-54CF-4D73-9BE3-BA3F90D9AD40Q39679283-939EF07C-39A7-45C1-8804-405ABCDF482FQ40064693-4960F1DC-67CC-408C-B318-DA03CF37E358
P50
description
hulumtues
@sq
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Colin W G Fishwick
@ast
Colin W G Fishwick
@cy
Colin W G Fishwick
@en
Colin W G Fishwick
@en-gb
Colin W G Fishwick
@es
Colin W G Fishwick
@nl
Colin W G Fishwick
@sl
type
label
Colin W G Fishwick
@ast
Colin W G Fishwick
@cy
Colin W G Fishwick
@en
Colin W G Fishwick
@en-gb
Colin W G Fishwick
@es
Colin W G Fishwick
@nl
Colin W G Fishwick
@sl
altLabel
Colin Fishwick
@cy
Colin Fishwick
@en
Colin Fishwick
@en-gb
prefLabel
Colin W G Fishwick
@ast
Colin W G Fishwick
@cy
Colin W G Fishwick
@en
Colin W G Fishwick
@en-gb
Colin W G Fishwick
@es
Colin W G Fishwick
@nl
Colin W G Fishwick
@sl
P185
P106
P1153
7003828441
P2031
1982-01-01T00:00:00Z
P21
P31
P496
0000-0003-1283-2181